Rapid sFLC assay shows good clinical concordance when compared with other sFLC assays
In a recent CCLM publication, the authors concluded that Seralite® FLC Serum, a quantitative lateral flow immunoassay, has shown good clinical concordance when compared with other sFLC assays.
By: Abingdon Health
The other clinically available sFLCS in question were N-Latex FLC (Siemens), Sebia FLC (Sebia) and Freelite (Binding Site).
The authors highlighted the importance sFLCs and why they are important in the screening of monoclonal gammopathies, prognostic stratification and monitoring response to therapies.
Chérina K.A. Fleming et al, analysed assay performance using 193 anonymous sera samples, with varying FLC-ratios, from patients with Multiple Myeloma (blood cancer) and other related conditions.
The study observed 'good agreements for κFLC, λFLC and FLC ratio between all four assays' and 'clinical concordances were high and ranged from 86% to 92%'.
Facilitating near-patient testing
The study also noted that Seralite's 'advantage' is that it can generate 'rapid FLC results using a portable diagnostic device, facilitating near-patient testing'.
Further details about this publication can be found at https://www.abingdonhealth.com/